Sunday, June 26, 2022

Buying Buzz: Humanigen Inc. [HGEN] Chief Scientific Officer Chappell Dale acquires 545,488 shares of the company

The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Humanigen Inc. shares valued at $1,215,347 were purchased by Chappell Dale on May 20. At $2.23 per share, Chappell Dale acquired 545,488 shares. The insider’s holdings grew to 8,675,081 shares worth approximately $21.17 million following the completion of this transaction.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Also, Chappell Dale purchased 323,808 shares, netting a total of over 707,844 in proceeds. Following the buying of shares at $2.19 each, the insider now holds 8,293,240 shares.

Before that, Chappell Dale had added 173,700 shares to its account. In a trade valued at $340,799, the Chief Scientific Officer bought Humanigen Inc. shares for $1.96 each. Upon closing the transaction, the insider’s holdings increased to 173,700 shares, worth approximately $19.68 million.

As published in a research note from Jefferies on September 10, 2021, Humanigen Inc. [HGEN] has been rated down from a Buy to a Hold and the price target has been revised to $9. This represents a 72.89% premium over Thursday’s closing price. Analysts at H.C. Wainwright resumed the stock at ‘”a Buy”‘ outlook in a report released in early September. As of September 09, 2021, JP Morgan has decreased its “Neutral” rating to a “an Underweight” for HGEN. Earlier on September 09, 2021, Credit Suisse downgraded its rating. Their new recommendation was “a Neutral” for HGEN stock which previously was a “an Outperform”.

Analyzing HGEN’s Price Performance

On Thursday, Humanigen Inc. [NASDAQ: HGEN] plunged -3.17% to $2.44. The stock’s lowest price that day was $2.36, but it reached a high of $2.575 in the same session. During the last five days, there has been a surge of approximately 7.49%. Over the course of the year, Humanigen Inc. shares have dropped approximately -34.41%. Shares of the company reached a 52-week high of $4.11 on 03/21/22 and a 52-week low of $1.67 on 02/24/22. A 50-day SMA is recorded $2.17, while a 200-day SMA reached $3.94. Nevertheless, trading volume fell to 1.14 million shares from 1.73 million shares the previous day.

Support And Resistance Levels for Humanigen Inc. (HGEN)

According to the 24-hour chart, there is a support level at 2.34, which, if violated, would cause prices to drop to 2.24. In the upper region, resistance lies at 2.56. The next price resistance is at 2.67. RSI (Relative Strength Index) is 54.35 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.07, which suggests the price will decrease in the coming days. Percent R is at 37.17%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.

Is Humanigen Inc. subject to short interest?

Stocks of Humanigen Inc. saw a sharp rise in short interest on May 30, 2022 jumping by 0.89 million shares to 7.22 million. Data from Yahoo Finance shows that the short interest on Apr 28, 2022 was 6.33 million shares. A jump of 12.33% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 4.87 of the overall float, the days-to-cover ratio (short ratio) jumped to 4.87.

Which companies own the most shares of Humanigen Inc. (HGEN)?

According to Black Horse Capital Management LL filings, the company currently owns 12,134,287 shares, which is about 17.18% of the total HGEN shares outstanding. The investor’s shares have appreciated by 1,042,996 from its previous 13-F filing of 11091291.0 shares. With the completion of the sale transaction, Valiant Capital Management LP’s stake is now worth $15,017,163. Murchinson Ltd. acquire a 16.67% interest valued at $11.45 million while BlackRock Fund Advisors purchased a 27,875 stake. A total of -56,705 shares of Humanigen Inc. were bought by The Vanguard Group, Inc. during the quarter, and 300,345 were bought by SSgA Funds Management, Inc. In its current portfolio, Marshall Wace LLP holds 1,232,968 shares valued at $2.69 million.

In terms of Humanigen Inc. share price expectations, FactSet research, analysts set an average price target of $17.80 in the next 12 months, up nearly 495.24% from the previous closing price of $2.52. Analysts anticipate Humanigen Inc. stock to reach $30.00 by 2022, with the lowest price target being $3.00. In spite of this, 6 analysts ranked Humanigen Inc. stock as an Overweight at the end of 2022. On June 11, 2021, Credit Suisse assigned a price target of “an Outperform” to the stock and initiated coverage with a $28.

Latest news

Related news


Please enter your comment!
Please enter your name here




Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam